Human serum attenuates the activity of protease inhibitors toward wild- type and mutant human immunodeficiency virus

Virology

Volumn 250, Issue 2, 1998, Pages 255-262

  Molla, Akhteruzzaman ^a   Vasavanonda, Sudthida ^a   Kumar, Gondi ^a   Sham, Hing L ^a   Johnson, Marianne ^a   Grabowski, Brian ^a   Denissen, Jon F ^a   Kohlbrenner, William ^a   Plattner, Jacob J ^a   Leonard, John M ^a   Norbeck, Daniel W ^a   Kempf, Dale J ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIVIRUS AGENT; INDINAVIR; LOPINAVIR; NELFINAVIR; PLASMA PROTEIN; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; DRUG POTENCY; DRUG PROTEIN BINDING; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROTEINASE INHIBITION; VIRUS INHIBITION; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0032566902     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1998.9383     Document Type: Article

References (30)

1. 1. J. Infect. Dis. 171:1995;546-551.
2. 1. Antimicrob. Agents Chemother. 40:1996;1491-1497.
3. Blaschke T. F. Protein binding and kinetics of drug in liver diseases. Clin. Pharmacokinet. 2:1977;32-44.
4. Cars O., Henning C., Holm S. E. Penetration of ampicillin and dicloxacillin into tissue case fluid in rabbits: Relation to serum and tissue protein binding. Scand. J. Infect. Dis. 1:1981;69-74.
5. Chou T.-C. The median-effect principle and the combination index for quantitation of synergism and antagonism. Synergism and Antagonism in Chemotherapy. 1991;Academic Press, San Diego. p. 65-69.
6. Danner S. A., Carr A., Leonard J. M., Lehman L. M., Gudiol F., Gonzales J., Raventos A., Rubio R., Bouza E., Pintado V., Gil Aguado A., Garcia de Lomas J., Delgado R., Borleffs J. C. C., Hsu A., Valdes J., Boucher C. A. B., Cooper D. A. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N. Engl. J. Med. 333:1995;1528-1533.
7. Denissen J. F., Grabowski B. A., Johnson M. K., Buko A. M., Kempf D. J., Thomas S. B., Surber B. W. Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs and humans. Drug Metab. Dispos. 25:1997;489-501.
8. Fischl M. A., Richman D. D., Flexner C., Para M. F., Haubrich R., Karim A., Yeramian P., Holden-Wiltse J., Meehan P. M. Phase I/II study of the toxicity, pharmacokinetics, and activity of the HIV protease inhibitor SC-52151. J. AIDS Human Retroviruses. 15:1997;28-34.
9. Hsu A., Granneman R., Witt G., Locke C., Denissen J., Molla A., Valdes J., Smith J., Erdman K., Lyons N., Niu P., Decourt J.-P., Fourtillan J.-B., Girault J., Leonard J. M. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob. Agents Chemother. 41:1997;898-905.
10. Jacobsen H., Haenggi M., Ott M., Duncan I. B., Vella S., Mous J. In vivo resistance to HIV proteinase inhibitor saquinavir - an update. AIDS Res. Human Retroviruses. 11:1995;S169.
11. Kageyama S., Anderson B. D., Hoesterey B. L., Hayashi H., Kiso Y., Flora K. P., Mitsuya H. Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteins. Antimicrob. Agents Chemother. 38:1994;1107-1111.
12. Keller F., Maiga M., Neumayer H. H., Lode H., Distler A. Pharmacokinetic effects of altered plasma protein binding of drugs in renal disease. Eur. J. Drug. Metab. Pharmacokinet. 9:1984;275-282.
13. Kempf D. J., Marsh K. C., Kumar G., Rodrigues A. D., Denissen J. F., McDonald E., Kukulka M. J., Hsu A., Granneman G. R., Baroldi P. A., Sun E., Pizzuti D., Plattner J. J., Norbeck D. W., Leonard J. M. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob. Agents Chemother. 41:1997;654-660.
14. Kohl N. E., Emini E. A., Schleif W. A., Davis L. J., Heimbach J. C., Dixon R. A. F., Scolnick E. M., Sigal I. S. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. USA. 85:1988;4686-4690.
15. Lazdins J. K., Mestan J., Goutte G., Walker M. R., Bold G., Capraro H. G., Klimkait T. In vitro effect of α1-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: A comparative study with other relevant HIV protease inhibitors. J. Infect. Dis. 175:1997;1063-1070.
16. Markowitz M., Saag M., Powderly W. G., Hurley A. M., Hsu A., Valdes J. M., Henry D., Sattler F., La Marca A., Leonard J. M., Ho D. D. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N. Eng. J. Med. 333:1995;1534-1539.
17. Meijer D. K. F., Van Der Sluijs P. The influence of albumin and alpha-1 acid glycoprotein on the clearance of drugs by the liver. Pharmacol. Weekbl. Sci. Ed. 9:1987;65-74.
18. Molla A., Korneyeva M., Gao Q., Vasavanonda S., Schipper P. J., Mo H.-M., Markowitz M., Chernyavskiy T., Niu P., Lyons N., Hsu A., Granneman G. R., D. H. D., Boucher C. A. B., Leonard J. M., Norbeck D. W., Kempf D. J. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med. 2:1996;760-766.
19. Noble S., Faulds D. Saquinavir - a review of its pharmacology and clinical potential in the management of HIV-infection. Drugs. 52:1996;93-112.
20. Pauwels R., Balzarini J., Baba M., Snoeck R., Schols D., Herdewijn P., Desmyter J., De Clercq E. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods. 20:1988;309-321.
21. Pearl L. H., Taylor W. R. Sequence specificity of retroviral proteases. Nature. 328:1987a;482.
22. Pearl L. H., Taylor W. R. A structural model for the retroviral proteases. Nature. 329:1987b;351-354.
23. Peterson L. R., Moody J. A., Fasching C. E., Gerding D. N. Influence of protein binding on therapeutic efficacy of cefoperazone. Antimicrob. Agents Chemother. 33:1989;566-568.
24. Peterson L. R., Van Etta R. L., Fasching C. E., Gerding D. N. Effect of protein binding on simulated intravascular and extravascular kinetics of cefotaxime in an in vitro model. Antimicrob. Agents Chemother. 25:1984;58-61.
25. Rowland M. Protein binding and drug clearance. Clin. Pharmacokinet. 9:1984;10-17.
26. Sham, H. L. Kempf, D. J. Molla, A. Marsh, K. C. Kumar, G. Chen, C.-M. Kati, W. Stewart, K. Lal, R. Hsu, A. Betebenner, D. Vasavanonda, S. McDonald, E. Saldivar, A. Wideburg, N. Chen, X. Niu, P. Park, C. Jayanti, V. Grabowski, B. Grenneman, G. R. Sun, E. Japour, A. J. Leonard, J. M. Plattner, J. J. Norbeck, D. W. 1998, ABT-378, a potent second generation inhibitor of the human immunodeficiency virus protease.
27. Shyu W. C., Quitiliani R., Nightingale C. H., Dudley M. N. Effect of protein binding on drug penetration into blister fluid. Antimicrob. Agents Chemother. 32:1988;128-130.
28. Stein D. S., Fish D. G., Bilello J. A., Preston S. L., Martineau G. L., Drusano G. L. A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS. 10:1996;485-492.
29. Vacca J. P., Dorsey B. D., Schlief W. A., Levin R. B., McDaniel S. L., Darke P. L., Zugay J., Quintero J. C., Blahy O. M., Roth E., Sardana V. V., Schlabach A. J., Graham P. I., Condra J. H., Gotlib L., Holloway M. K., Lin J., Chen I.-W., Vastag K., Ostovic D., Anderson P. S., Emini E. A., Huff J. R. L-735524: An orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc. Natl. Acad. Sci. USA. 91:1994;4096-4100.
30. Wise R. The clinical relevance of protein binding and tissue concentrations in antimicrobial therapy. Clin. Pharmacokinet. 11:1986;470-482.